SOURCE: LifeSci Advisors

LifeSci Advisors

December 10, 2013 08:00 ET

LifeSci Advisors Initiates Coverage of Immune Pharmaceuticals

Lead Candidate Bertilimumab Is in Phase II Trials for Inflammatory Bowel Diseases and Bullous Pemphigoid; Report Available for Download at

NEW YORK, NY--(Marketwired - Dec 10, 2013) - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP) (OTCQX: IMNP), a clinical stage biopharmaceutical company focused on developing antibody therapeutics for inflammatory diseases and cancer. Immune Pharmaceuticals' lead development program is bertilimumab, currently in Phase II clinical trials for treatment of ulcerative colitis (UC), Crohn's disease (CD) and bullous pemphigoid (BP), an orphan, autoimmune dermatological condition. Data from trials of bertilimumab in BP and CD are expected in mid-2014, and data from the UC trial is expected in the first half of 2015.

"Immune Pharmaceuticals' bertilimumab development program has the potential to offer a treatment with a differentiated mechanism of action for patients with inflammatory bowel disease and other inflammatory conditions," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "By targeting eotaxin-1, bertilimumab has the potential to be an effective treatment for IBD, bullous pemphigoid, severe asthma, and chronic obstructive pulmonary disease."

Immune Pharmaceuticals has a deep therapeutic pipeline focused on improving the lives of patients with inflammatory diseases and cancer. Lead product candidate bertilimumab is a first-in-class, fully human monoclonal antibody that targets eotaxin, a mediator of inflammation, angiogenesis, and neurogenesis. The Company is also developing the NanomAb platform, an antibody-conjugated, chemotherapy-loaded nanoparticle, to specifically target cancer drugs to cancer cells, with the goal of producing greater efficacy while reducing off-target effects. AmiKet, a topical analgesic cream for the treatment of peripheral neuropathies, has shown efficacy in Phase II trials and has received Fast Track designation for a Phase III trial in chemotherapy induced peripheral neuropathy. This program has the potential to generate licensing revenues as early as 2014.

In a 25 page Initiation Report by LifeSci Advisors, we explain the clinical development plans for Immune Pharmaceuticals' programs. The report details the therapeutic potential of bertilimumab in multiple indications, including clinical trial data compiled to date. We also highlight Immune's pipeline of promising therapeutic candidates including Amiket for the treatment of peripheral neuropathy and those based on the NanomAb platform.

Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.

The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.

About LifeSci Advisors:

LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website,

Important Disclosures:

The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.

Contact Information